Aclaris Therapeutics (ACRS) Earnings Date & Reports

Key Takeaways

• Aclaris Therapeutics (ACRS) reported a third quarter 2026 net loss of $18.5 million, widening from $14.6 million in the same period a year earlier.
• GAAP (Generally Accepted Accounting Principles) loss per share came in at $0.12, beating the consensus estimate of a $0.16 loss.
• Revenue of $1.48 million topped analyst expectations, though it declined from $3.3 million a year ago due to a prior-year Sun Pharma milestone.
• Management highlighted positive Phase 1b proof-of-concept data for ATI-052 in atopic dermatitis and asthma as the quarter's headline clinical catalyst.
• The company reaffirmed cash guidance, extending its runway through the first half of 2029 following an October equity offering.
• For more on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages on Tickeron.
• Discover automated trading ideas by exploring Trending AI Robots.

Earnings Context and Why It Matters

As a clinical-stage biopharmaceutical company, Aclaris Therapeutics generates modest revenue while its value story rests almost entirely on the progress of its immuno-inflammatory drug pipeline. Quarterly earnings therefore serve less as a test of profitability and more as a checkpoint on clinical execution, spending discipline, and cash runway. Heading into this report, investors were focused on whether ATI-052 could validate its promise in atopic dermatitis and asthma, and whether the company's balance sheet could support a growing slate of mid-stage trials. With multiple Phase 2 readouts and regulatory filings scheduled across late 2026 and 2027, this quarter offered a critical look at how well Aclaris is converting its earlier-stage programs into late-stage catalysts.

Reported Results

Aclaris Therapeutics reported a net loss of $18.5 million for the third quarter of 2026, compared with $14.6 million a year earlier. GAAP loss per share was $0.12, narrower than the consensus estimate of a $0.16 loss. Total revenue reached $1.48 million, above the roughly $1.2 million analysts had expected, but down from $3.3 million in the prior-year period. The revenue decline primarily reflected a sales milestone recognized under the Sun Pharma license agreement in the third quarter of 2025.

Research and development (R&D) expenses rose to $16.1 million from $13.0 million, driven by ATI-052 manufacturing and clinical costs plus ATI-9494 development. General and administrative (G&A) expenses increased to $6.0 million from $4.9 million. For the nine months ended September 30, 2026, revenue was $5.1 million and the net loss was $59.8 million, compared with $6.5 million and $45.1 million in the prior-year period.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of securities with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. For a pipeline-driven biotech name like Aclaris, the screener can help surface comparable stocks and identify trade ideas, trending tickers, and breakout candidates more efficiently than manual screening. Explore the AI Screener to see how its signals and filters can support your own market research.

Market Reaction and Investor Sentiment

Investor attention around this report centered on the clinical narrative rather than the bottom line. The positive primary analysis from ATI-052's Phase 1b proof-of-concept trials in atopic dermatitis and asthma reinforced confidence in the company's antibody platform, while management's decision to prioritize a Phase 2b program in eosinophilic esophagitis signaled disciplined capital allocation. At the same time, the quarter reflected rising R&D spend and a wider net loss, and a recent discounted equity offering introduced dilution concerns. Sentiment remained balanced between enthusiasm for near-term data catalysts and caution around the cost of advancing a multi-program pipeline.

Forward Outlook and Key Factors to Monitor

Looking ahead, Aclaris has packed the coming months with clinical and regulatory milestones that investors will be watching closely. The Phase 2 ADMIRATION trial of bosakitug (ATI-045) in moderate-to-severe atopic dermatitis is expected to deliver top-line results in the fourth quarter of 2026, a readout that could meaningfully shape sentiment around the antibody franchise.

In parallel, the company expects to initiate a Phase 2b trial of modzatinib (ATI-2138) in lichen planus during the fourth quarter of 2026, with first site activation anticipated in November. The filing of an Investigational New Drug (IND) application for ATI-9494, an oral dual ITK/TXK inhibitor, also remains on track for the fourth quarter. These catalysts position late 2026 as a pivotal window for the pipeline.

On the financial side, Aclaris reported $204.6 million in cash, cash equivalents, and marketable securities as of September 30, 2026. Combined with a $50 million October offering, management believes the runway extends through the first half of 2029. Investors will continue to monitor R&D expense growth, future financing decisions, and whether upcoming data readouts justify the company's expanding clinical investment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations